Baxter International, Inc. (BAX) Tops Q2 EPS by 4c; Guides Q3 EPS
Get Alerts BAX Hot Sheet
Revenue Growth %: -2.7%
Financial Fact:
Research and development expenses: 159M
Today's EPS Names:
CPSS, HARL, MCET, More
Join SI Premium – FREE
Baxter International, Inc. (NYSE: BAX) reported Q2 EPS of $1.26, 4 cents better than the analyst estimate of $1.22. Revenue for the quarter came in at $4.3 billion versus the consensus estimate of $4.12 billion.
Baxter International, Inc. sees Q3 2014 EPS of $1.28-$1.32, versus the consensus of $1.32. The company expects sales growth of approximately 12 to 13 percent.
Baxter now expects sales growth for full-year 2014 of 10 to 11 percent, before the impact of foreign exchange. Also for the full year, Baxter expects earnings, before special items, of $5.10 to $5.20 per diluted share and cash flows from operations of approximately $3.5 billion, excluding cash costs related to the spin-off of the biopharmaceutical business.
For earnings history and earnings-related data on Baxter International, Inc. (BAX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Abbott (ABT) Tops Q1 EPS by 2c, Offers Guidance
- Stephens Reiterates Equal Weight Rating on Hancock Whitney (HWC)
- Adidas (ADDYY) stock rises after outlook boost
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Earnings, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!